Medicare contractor Noridian Healthcare Solutions Medicare has withdrawn a deep reimbursement cut to robotic stereotactic radiosurgery/stereotactic body radiation therapy planned for January 1, 2019, and has reduced cuts that were supposed to go into effect on July 1, according to the American College of Radiology (ACR).
Noridian announced a 60% cut in April for robotic stereotactic radiosurgery/stereotactic body radiation therapy that would take effect on July 1. In June, it announced that this cut would be reduced to 20% until January 1, 2019, when the 60% reduction would be implemented. However, in July Noridian announced that it is postponing the additional 40% cut indefinitely, the ACR said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
